Antibody distance from the cell membrane regulates antibody effector mechanisms
Antibody distance from the cell membrane regulates antibody effector mechanisms
Immunotherapy using mAbs, such as rituximab, is an established means of treating hematological malignancies. Abs can elicit a number of mechanisms to delete target cells, including complement-dependent cytotoxicity, Ab-dependent cellular cytotoxicity, and Ab-dependent cellular phagocytosis. The inherent properties of the target molecule help to define which of these mechanisms are more important for efficacy. However, it is often unclear why mAb binding to different epitopes within the same target elicits different levels of therapeutic activity. To specifically address whether distance from the target cell membrane influences the aforementioned effector mechanisms, a panel of fusion proteins consisting of a CD20 or CD52 epitope attached to various CD137 scaffold molecules was generated. The CD137 scaffold was modified through the removal or addition of cysteine-rich extracellular domains to produce a panel of chimeric molecules that held the target epitope at different distances along the protein. It was shown that complement-dependent cytotoxicity and Ab-dependent cellular cytotoxicity favored a membrane-proximal epitope, whereas Ab-dependent cellular phagocytosis favored an epitope positioned further away. These findings were confirmed using reagents targeting the membrane-proximal or -distal domains of CD137 itself before investigating these properties in vivo, where a clear difference in the splenic clearance of transfected tumor cells was observed. Together, this work demonstrates how altering the position of the Ab epitope is able to change the effector mechanisms engaged and facilitates the selection of mAbs designed to delete target cells through specific effector mechanisms and provide more effective therapeutic agents.
3999-4011
Cleary, Kirstie
16e11432-9855-4b5b-8c3f-be86f0ef51f0
Chan, H.T. Claude
b109c93f-7e9a-44ee-ad12-da757b1b11fc
James, Sonya
764c80e3-5bea-4b34-a871-b43f87ef97b0
Glennie, Martin J.
9f6f0eff-4560-48c2-80cd-0ec116110ded
Cragg, Mark S.
ec97f80e-f3c8-49b7-a960-20dff648b78c
15 May 2017
Cleary, Kirstie
16e11432-9855-4b5b-8c3f-be86f0ef51f0
Chan, H.T. Claude
b109c93f-7e9a-44ee-ad12-da757b1b11fc
James, Sonya
764c80e3-5bea-4b34-a871-b43f87ef97b0
Glennie, Martin J.
9f6f0eff-4560-48c2-80cd-0ec116110ded
Cragg, Mark S.
ec97f80e-f3c8-49b7-a960-20dff648b78c
Cleary, Kirstie, Chan, H.T. Claude, James, Sonya, Glennie, Martin J. and Cragg, Mark S.
(2017)
Antibody distance from the cell membrane regulates antibody effector mechanisms.
The Journal of Immunology, 198 (10), .
(doi:10.4049/jimmunol.1601473).
Abstract
Immunotherapy using mAbs, such as rituximab, is an established means of treating hematological malignancies. Abs can elicit a number of mechanisms to delete target cells, including complement-dependent cytotoxicity, Ab-dependent cellular cytotoxicity, and Ab-dependent cellular phagocytosis. The inherent properties of the target molecule help to define which of these mechanisms are more important for efficacy. However, it is often unclear why mAb binding to different epitopes within the same target elicits different levels of therapeutic activity. To specifically address whether distance from the target cell membrane influences the aforementioned effector mechanisms, a panel of fusion proteins consisting of a CD20 or CD52 epitope attached to various CD137 scaffold molecules was generated. The CD137 scaffold was modified through the removal or addition of cysteine-rich extracellular domains to produce a panel of chimeric molecules that held the target epitope at different distances along the protein. It was shown that complement-dependent cytotoxicity and Ab-dependent cellular cytotoxicity favored a membrane-proximal epitope, whereas Ab-dependent cellular phagocytosis favored an epitope positioned further away. These findings were confirmed using reagents targeting the membrane-proximal or -distal domains of CD137 itself before investigating these properties in vivo, where a clear difference in the splenic clearance of transfected tumor cells was observed. Together, this work demonstrates how altering the position of the Ab epitope is able to change the effector mechanisms engaged and facilitates the selection of mAbs designed to delete target cells through specific effector mechanisms and provide more effective therapeutic agents.
Text
65657_2_merged_1489683521
- Accepted Manuscript
Restricted to Repository staff only
Request a copy
Text
65657_2_merged_1489683521
Restricted to Repository staff only
Request a copy
More information
Accepted/In Press date: 16 March 2017
e-pub ahead of print date: 12 April 2017
Published date: 15 May 2017
Organisations:
Cancer Sciences, Human Development & Health
Identifiers
Local EPrints ID: 410692
URI: http://eprints.soton.ac.uk/id/eprint/410692
PURE UUID: 885fa2f3-0519-4efe-9a20-10c84c315876
Catalogue record
Date deposited: 09 Jun 2017 09:22
Last modified: 16 Mar 2024 04:23
Export record
Altmetrics
Contributors
Author:
Kirstie Cleary
Author:
H.T. Claude Chan
Author:
Sonya James
Download statistics
Downloads from ePrints over the past year. Other digital versions may also be available to download e.g. from the publisher's website.
View more statistics